导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.06% | 2491/4773 |
| 近一周 | -2.22% | 1525/5462 |
| 近一月 | -4.11% | 2222/5421 |
| 近一季 | -7.55% | 2444/5209 |
| 近半年 | -2.23% | 1831/4920 |
| 近一年 | 1.85% | 2252/4366 |
| 近两年 | 50.34% | 1454/2954 |
| 近三年 | 31.17% | 1008/2253 |
| 成立以来 | 53.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.34% 3143/4961 |
13.07% 2069/5312 |
- - |
- - |
| 2025 | 22.12% 1997/4813 |
-0.66% 2343/3635 |
2.80% 1346/4076 |
18.90% 2229/4524 |
0.58% 1925/4813 |
| 2024 | 17.20% 715/3463 |
2.98% 643/2808 |
-1.25% 1004/3014 |
17.69% 1140/3129 |
-2.08% 1949/3463 |
| 2023 | -9.60% 1199/2656 |
4.44% 951/2280 |
-4.18% 1078/2385 |
-2.99% 819/2515 |
-6.89% 1961/2655 |
| 2022 | -20.14% 938/2207 |
-14.23% 920/1919 |
6.81% 601/2016 |
-14.37% 1081/2113 |
1.79% 1138/2208 |
| 2021 | -0.14% 741/1822 |
-1.88% 549/1255 |
5.62% 799/1330 |
-5.83% 867/1466 |
2.32% 625/1822 |
| 2020 | - - |
- - |
- - |
15.01% 243/1164 |
16.44% 171/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时沪深300ETF VS. 长安沪深300非周期A(740101) |